BR112017008280A2 - método para o tratamento de um paciente - Google Patents
método para o tratamento de um pacienteInfo
- Publication number
- BR112017008280A2 BR112017008280A2 BR112017008280-2A BR112017008280A BR112017008280A2 BR 112017008280 A2 BR112017008280 A2 BR 112017008280A2 BR 112017008280 A BR112017008280 A BR 112017008280A BR 112017008280 A2 BR112017008280 A2 BR 112017008280A2
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- treating
- cell carcinoma
- hpv
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 206010004146 Basal cell carcinoma Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 206010041823 squamous cell carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068332P | 2014-10-24 | 2014-10-24 | |
| US62/068,332 | 2014-10-24 | ||
| PCT/US2015/057150 WO2016065281A1 (en) | 2014-10-24 | 2015-10-23 | Cancer and skin lesion treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017008280A2 true BR112017008280A2 (pt) | 2018-01-02 |
Family
ID=55761638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017008280-2A BR112017008280A2 (pt) | 2014-10-24 | 2015-10-23 | método para o tratamento de um paciente |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10238729B2 (https=) |
| EP (1) | EP3209676A4 (https=) |
| JP (1) | JP6663438B2 (https=) |
| KR (1) | KR102285401B1 (https=) |
| CN (1) | CN107001430A (https=) |
| AU (1) | AU2015335652B2 (https=) |
| BR (1) | BR112017008280A2 (https=) |
| CA (1) | CA2965498A1 (https=) |
| CL (1) | CL2017001008A1 (https=) |
| IL (1) | IL251825B2 (https=) |
| MX (1) | MX395186B (https=) |
| MY (1) | MY195018A (https=) |
| PH (1) | PH12017500754A1 (https=) |
| SG (1) | SG11201703262UA (https=) |
| WO (1) | WO2016065281A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019506435A (ja) * | 2016-02-27 | 2019-03-07 | エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. | ワクチンを使用して癌または皮膚病変を治療するための方法および組成物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2284559T3 (es) * | 2001-03-23 | 2007-11-16 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Genes y proteinas e6 y e7 modificados del vph utiles como vacuna. |
| GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
| US20060222656A1 (en) | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| GB0206359D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0222953D0 (en) * | 2002-10-03 | 2002-11-13 | Glaxo Group Ltd | Novel Compounds |
| WO2004056389A1 (en) | 2002-12-20 | 2004-07-08 | Glaxosmithkline Biologicals Sa | Hpv-16 and -18 l1 vlp vaccine |
| PE20060434A1 (es) * | 2004-06-16 | 2006-06-08 | Glaxosmithkline Biolog Sa | Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph |
| GB0417430D0 (en) | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
| US8399610B2 (en) | 2004-08-05 | 2013-03-19 | University College Cardiff Consultants Limited | HPV vaccine comprising peptides from host cell proteins |
| WO2008112125A1 (en) * | 2007-03-09 | 2008-09-18 | Merck & Co., Inc. | Papillomavirus vaccine compositions |
| CN101530614A (zh) * | 2008-03-10 | 2009-09-16 | 北京康乐卫士生物技术有限公司 | 五价重组人乳头瘤病毒疫苗 |
| CN101530612A (zh) * | 2008-03-10 | 2009-09-16 | 北京康乐卫士生物技术有限公司 | 16型重组人乳头瘤病毒疫苗 |
| US20110110979A1 (en) | 2008-04-16 | 2011-05-12 | Universite De Lausanne | Method and vaccine for optimizing the specific immune responses |
| WO2010118424A2 (en) * | 2009-04-10 | 2010-10-14 | The Johns Hopkins University | Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines |
| EP3427755B1 (en) * | 2009-04-13 | 2020-10-21 | INSERM - Institut National de la Santé et de la Recherche Médicale | Hpv particles and uses thereof |
| CN101890160B (zh) * | 2009-04-28 | 2014-06-18 | 北京康乐卫士生物技术有限公司 | 多价重组人乳头瘤病毒疫苗及其应用 |
| US9566323B2 (en) | 2009-06-19 | 2017-02-14 | Eyegene Inc. | Vaccine for cervical cancer |
| SG177269A1 (en) * | 2009-06-25 | 2012-02-28 | Glaxosmithkline Biolog Sa | Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease |
| AR074485A1 (es) * | 2009-12-04 | 2011-01-19 | Consejo Nac Invest Cient Tec | Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos |
| JP2014516075A (ja) * | 2011-06-06 | 2014-07-07 | シェブロン フィリップス ケミカル カンパニー エルピー | 癌治療のためのメタロセン化合物の使用 |
| US20130064849A1 (en) * | 2011-07-14 | 2013-03-14 | The Board Of Regents Of The University Of Texas | Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines |
| WO2013139744A1 (en) * | 2012-03-18 | 2013-09-26 | Glaxosmithkline Biologicals S.A. | Method of vaccination against human papillomavirus |
| US20150086587A1 (en) * | 2012-03-28 | 2015-03-26 | Kansas State University Research Foundation | Vaccine adjuvant |
| US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9974849B2 (en) | 2013-10-13 | 2018-05-22 | Bioventures, Llc | Human Papilloma virus therapeutic vaccine |
-
2015
- 2015-10-23 CN CN201580064634.6A patent/CN107001430A/zh active Pending
- 2015-10-23 WO PCT/US2015/057150 patent/WO2016065281A1/en not_active Ceased
- 2015-10-23 EP EP15853497.4A patent/EP3209676A4/en not_active Ceased
- 2015-10-23 US US14/921,648 patent/US10238729B2/en active Active
- 2015-10-23 IL IL251825A patent/IL251825B2/en unknown
- 2015-10-23 MX MX2017005418A patent/MX395186B/es unknown
- 2015-10-23 JP JP2017540976A patent/JP6663438B2/ja active Active
- 2015-10-23 AU AU2015335652A patent/AU2015335652B2/en active Active
- 2015-10-23 SG SG11201703262UA patent/SG11201703262UA/en unknown
- 2015-10-23 KR KR1020177013441A patent/KR102285401B1/ko active Active
- 2015-10-23 CA CA2965498A patent/CA2965498A1/en active Pending
- 2015-10-23 MY MYPI2017000594A patent/MY195018A/en unknown
- 2015-10-23 BR BR112017008280-2A patent/BR112017008280A2/pt not_active Application Discontinuation
-
2017
- 2017-04-24 PH PH12017500754A patent/PH12017500754A1/en unknown
- 2017-04-24 CL CL2017001008A patent/CL2017001008A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2965498A1 (en) | 2016-04-28 |
| PH12017500754A1 (en) | 2017-10-30 |
| KR102285401B1 (ko) | 2021-08-02 |
| JP2017531699A (ja) | 2017-10-26 |
| IL251825B1 (en) | 2023-05-01 |
| CL2017001008A1 (es) | 2017-11-24 |
| WO2016065281A1 (en) | 2016-04-28 |
| MX2017005418A (es) | 2017-11-30 |
| CN107001430A (zh) | 2017-08-01 |
| US20160114023A1 (en) | 2016-04-28 |
| MY195018A (en) | 2023-01-03 |
| US10238729B2 (en) | 2019-03-26 |
| AU2015335652B2 (en) | 2020-07-02 |
| IL251825A0 (en) | 2017-06-29 |
| MX395186B (es) | 2025-03-21 |
| EP3209676A1 (en) | 2017-08-30 |
| KR20170072279A (ko) | 2017-06-26 |
| AU2015335652A1 (en) | 2017-05-25 |
| EP3209676A4 (en) | 2018-03-28 |
| SG11201703262UA (en) | 2017-05-30 |
| JP6663438B2 (ja) | 2020-03-11 |
| IL251825B2 (en) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ732211A (en) | Combination immunotherapy approach for treatment of cancer | |
| MX372883B (es) | Uso de anticuerpos contra claudina 18.2 para el tratamiento de cáncer. | |
| EP4691562A3 (en) | Anti-pd-l1 combinations for treating tumors | |
| NZ749218A (en) | Androgen receptor modulator and uses thereof | |
| JO3735B1 (ar) | مركبات ألكين بها استبدال رباعي واستخداماتها | |
| CO2017004932A2 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
| NZ746338A (en) | Use of alphavirus and zap inhibitor in the preparation of an antitumor drug, and antitumor drugs comprising the same | |
| TN2017000554A1 (en) | Novel combination for use in the treatment of cancer | |
| MX393612B (es) | Vacuna contra viruela para tratamiento del cancer. | |
| AU2015329999B2 (en) | 17a,21-diesters of cortexolone for use in the treatment of tumors | |
| MX373231B (es) | Agente anticancerigeno. | |
| EP4552698A3 (en) | Methods of treating prostate cancer | |
| EP4599893A3 (en) | Cg0070 for treating bcg resistant bladder carcinoma in situ | |
| HK1258319A1 (zh) | 癌症疗法 | |
| BR112017002809A2 (pt) | métodos para tratar câncer cervical | |
| BR112017021700A2 (pt) | composições terapêuticas e métodos de uso para o tratamento do câncer | |
| IN2014MU00303A (https=) | ||
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| AU2016206832A8 (en) | Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs | |
| TW201613587A (en) | Medical treatments based on anamorelin | |
| PH12018500254A1 (en) | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof | |
| PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| HK1250626A1 (zh) | 借助塞里班土单抗的组合治疗 | |
| NZ734750A (en) | Cancer therapy with a parvovirus combined with bevacizumab | |
| MY181685A (en) | Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |